A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leu...

por Klisovic, Rebecca B., Leung, Wing H., Brugger, Wolfram, Dirnberger‐Hertweck, Maren, Winderlich, Mark, Ambarkhane, Sumeet V., Jabbour, Elias J.
Publicado 2021

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

por Nguyen, Rosa, Sahr, Natasha, Sykes, April, McCarville, Mary Beth, Federico, Sara M, Sooter, Amanda, Cullins, David, Rooney, Barbara, Janssen, William E, Talleur, Aimee C, Triplett, Brandon M, Anthony, Gwendolyn, Dyer, Michael A, Pappo, Alberto S, Leung, Wing H, Furman, Wayne L
Publicado 2020

Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy

por Pui, Ching-Hon, Pei, Deqing, Raimondi, Susana C, Coustan-Smith, Elaine, Jeha, Sima, Cheng, Cheng, Bowman, W Paul, Sandlund, John T, Ribeiro, Raul C, Rubnitz, Jeffrey E, Inaba, Hiroto, Gruber, Tanja A, Leung, Wing H, Yang, Jun J, Downing, James R, Evans, William E, Relling, Mary V, Campana, Dario
Publicado 2016